Compound A Select compound… 5-Amino-1MQ Amlexanox AOD-9604 Argireline BPC-157 Buserelin Carnosine Cerebrolysin CJC-1295 Cortexin Crystagen Dihexa DSIP Epithalon Follistatin 344 FOXO4-DRI GHK GHRP-2 GHRP-6 Glandokort Gonadorelin hCG HGH Fragment 176-191 Humanin IGF-1 DES IGF-1 LR3 Ipamorelin Kisspeptin KPV Liraglutide Livagen LL-37 Melanotan I Melanotan II MK-677 MOTS-c NAD+ Noopept NSI-189 Oxytocin P21 PEG-MGF Pramlintide PT-141 Retatrutide Retinalamin Selank Semaglutide Semax Sermorelin SS-31 Svetinorm TB-500 Tesamorelin Tesofensine Thymalin Thymosin Alpha-1 Tirzepatide Triptorelin Ventfort Vesugen Vilon VIP
vs
Compound B Select compound… 5-Amino-1MQ Amlexanox AOD-9604 Argireline Buserelin Carnosine Cerebrolysin CJC-1295 Cortexin Crystagen Dihexa DSIP Epithalon Follistatin 344 FOXO4-DRI GHK GHK-Cu GHRP-2 GHRP-6 Glandokort Gonadorelin hCG HGH Fragment 176-191 Humanin IGF-1 DES IGF-1 LR3 Ipamorelin Kisspeptin KPV Liraglutide Livagen LL-37 Melanotan I Melanotan II MK-677 MOTS-c NAD+ Noopept NSI-189 Oxytocin P21 PEG-MGF Pramlintide PT-141 Retatrutide Retinalamin Selank Semaglutide Semax Sermorelin SS-31 Svetinorm TB-500 Tesamorelin Tesofensine Thymalin Thymosin Alpha-1 Tirzepatide Triptorelin Ventfort Vesugen Vilon VIP
Molecular weight
1419.53 g/mol
340.38 g/mol
Half-life
~4 hours (stable in gastric juice — unique among peptides)
~1 hour (injectable); variable topical absorption
Admin routes
subcutaneous intramuscular oral topical
topical subcutaneous intradermal
Research areas
Tendon/ligament repair Gut healing (IBD, ulcers, leaky gut) Muscle injury recovery Neuroprotection Bone fracture healing Wound healing Organ protection (liver, pancreas, heart)
Skin rejuvenation / anti-aging Wound healing Hair growth / follicle stimulation Lung fibrosis / COPD repair Anti-inflammatory Bone regeneration Nerve regeneration
Typical dosing
250–500 mcg · 1-2x daily · 4-12 weeks
200–500 mcg · 1x daily (injectable); 1-2x daily (topical) · 4-8 weeks (injectable); ongoing (topical)
FDA status
Not FDA-approved. Category 2 per FDA's 503A bulk drug substance framework (demonstrably difficult to compound). Previously Category 1 as of Feb 2026 reclassification — verify current status.
Not FDA-approved as drug. Available OTC in cosmetic formulations. Category 1 under 503A bulk drug substance framework (compoundable) for injectable use.
WADA status
Prohibited (S0 category — non-approved substances, effective January 2022)
Not prohibited (as of 2026)
